French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...

Sanofi (SNY), a French pharmaceutical and healthcare company, Friday announced that it is executing the second tranche of its share ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

In other deals, Linklaters, Willkie and Latham are advising as PAI Partners negotiates to buy a stake in Alvest, a France-based provider of ground support equipment for airports, in a deal worth an ...

French pharmaceutical and healthcare company Sanofi on Friday announced a share buyback plan worth up to €2 billion ($2.08 ...

Sanofi has officially opened a modular biologics ... companion to an EVF already up and running in Neuville-sur-Saône in France. The concept behind the EVF was inspired by plants used in the ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

Copyright © 2025 MarketWatch, Inc. All rights reserved.

(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 12,601.67 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...